The subject of this publication is the conclusion of agreements in accordance with Section 130 a (8) SGB V on finished medicinal products with various active substances or combinations of active substances within the framework of a so-called “open house model”.

The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out.

The earliest contract start date is June 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on May 31, 2022 regardless of the start of the contract.

If AOK Hessen should carry out an invitation to tender for exclusive contracts in the form of an open procedure during the contract period, the contracts concluded as part of this publication will be terminated in accordance with the contractual regulations.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact I.1. Request the participation documents and the contract from the contact address given. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company must complete and sign the requested participation documents. With any pharmaceutical company that meets the eligibility requirements

a contract is concluded. There is no exclusivity. This publication is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are due solely to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact I.1. Request the participation documents and the contract from the contact address given. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company must complete and sign the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. There is no exclusivity. This publication is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are due solely to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact I.1. Request the participation documents and the contract from the contact address given. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company must complete and sign the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. There is no exclusivity. This publication is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are due solely to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.